Cargando…

Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil

The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain–Barré syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mengge, Deng, Chao, Liu, Xianling, Jiang, Shun, Gao, Yuan, Fan, Dan, Zhou, Yiguang, He, Jiangbo, Liu, Chaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200921/
https://www.ncbi.nlm.nih.gov/pubmed/37223099
http://dx.doi.org/10.3389/fimmu.2023.1132692
_version_ 1785045155869360128
author Ding, Mengge
Deng, Chao
Liu, Xianling
Jiang, Shun
Gao, Yuan
Fan, Dan
Zhou, Yiguang
He, Jiangbo
Liu, Chaoyuan
author_facet Ding, Mengge
Deng, Chao
Liu, Xianling
Jiang, Shun
Gao, Yuan
Fan, Dan
Zhou, Yiguang
He, Jiangbo
Liu, Chaoyuan
author_sort Ding, Mengge
collection PubMed
description The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain–Barré syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously due to the self-limited nature of the disease, but severe cases can result in respiratory failure or even death. Here we report a rare case of GBS occurring in a 58-year-old male patient with non-small cell lung cancer (NSCLC) who developed muscle weakness and numbness of the extremities during chemotherapy combined with KN046, a PD-L1/CTLA-4 bispecific antibody. Despite receiving methylprednisolone and γ-globulin, the patient’s symptoms did not improve. However, there was significant improvement after treatment with mycophenolate mofetil (MM) capsules, which is not a routine regimen for GBS. To the best of our knowledge, this is the first reported case of ICIs-induced GBS that responded well to mycophenolate mofetil instead of methylprednisolone or γ-globulin. Thus, it provides a new treatment option for patients with ICIs-induced GBS.
format Online
Article
Text
id pubmed-10200921
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102009212023-05-23 Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil Ding, Mengge Deng, Chao Liu, Xianling Jiang, Shun Gao, Yuan Fan, Dan Zhou, Yiguang He, Jiangbo Liu, Chaoyuan Front Immunol Immunology The emergence of immune checkpoint inhibitors (ICIs) has significantly prolonged the survival time of cancer patients. However, it may also lead to various immune-related adverse events (irAEs), including Guillain–Barré syndrome (GBS), a rare type of irAE. Most GBS patients can recover spontaneously due to the self-limited nature of the disease, but severe cases can result in respiratory failure or even death. Here we report a rare case of GBS occurring in a 58-year-old male patient with non-small cell lung cancer (NSCLC) who developed muscle weakness and numbness of the extremities during chemotherapy combined with KN046, a PD-L1/CTLA-4 bispecific antibody. Despite receiving methylprednisolone and γ-globulin, the patient’s symptoms did not improve. However, there was significant improvement after treatment with mycophenolate mofetil (MM) capsules, which is not a routine regimen for GBS. To the best of our knowledge, this is the first reported case of ICIs-induced GBS that responded well to mycophenolate mofetil instead of methylprednisolone or γ-globulin. Thus, it provides a new treatment option for patients with ICIs-induced GBS. Frontiers Media S.A. 2023-05-08 /pmc/articles/PMC10200921/ /pubmed/37223099 http://dx.doi.org/10.3389/fimmu.2023.1132692 Text en Copyright © 2023 Ding, Deng, Liu, Jiang, Gao, Fan, Zhou, He and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ding, Mengge
Deng, Chao
Liu, Xianling
Jiang, Shun
Gao, Yuan
Fan, Dan
Zhou, Yiguang
He, Jiangbo
Liu, Chaoyuan
Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title_full Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title_fullStr Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title_full_unstemmed Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title_short Case Report: ICIs-induced Guillain–Barré syndrome recovered from mycophenolate mofetil
title_sort case report: icis-induced guillain–barré syndrome recovered from mycophenolate mofetil
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200921/
https://www.ncbi.nlm.nih.gov/pubmed/37223099
http://dx.doi.org/10.3389/fimmu.2023.1132692
work_keys_str_mv AT dingmengge casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT dengchao casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT liuxianling casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT jiangshun casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT gaoyuan casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT fandan casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT zhouyiguang casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT hejiangbo casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil
AT liuchaoyuan casereporticisinducedguillainbarresyndromerecoveredfrommycophenolatemofetil